Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Last week, Eli Lilly said it would cut the monthly price of its starter ... WATCH: Lawmakers challenge drug company CEO over ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

Last week, Eli Lilly said it would cut the monthly price ... the drugs during the shortage will have to wind down production. Wegovy and Zepbound are part of a GLP-1 class of treatments that ...

Strong demand for both Wegovy and Eli Lilly’s Zepbound led to shortages of those products. Compounding pharmacies pounced, taking market share with their custom-made, lower-cost versions of GLP ...

The discounted price is aimed at uninsured patients and those whose insurance doesn't cover weight-loss medications like Wegovy. The move follows a similar price reduction by competitor Eli Lilly ...

Wegovy’s maker, Novo Nordisk, is charging $499 per month for its direct-to-consumer product. Customers can’t get their health insurance to pay for the either Eli Lilly’s Zepbound vials or ...